253 related articles for article (PubMed ID: 25124653)
21. 2-Oxoglutarate-dependent dioxygenases in cancer.
Losman JA; Koivunen P; Kaelin WG
Nat Rev Cancer; 2020 Dec; 20(12):710-726. PubMed ID: 33087883
[TBL] [Abstract][Full Text] [Related]
22. Genetic alterations in Krebs cycle and its impact on cancer pathogenesis.
Sajnani K; Islam F; Smith RA; Gopalan V; Lam AK
Biochimie; 2017 Apr; 135():164-172. PubMed ID: 28219702
[TBL] [Abstract][Full Text] [Related]
23. Detection, mechanisms, and therapeutic implications of oncometabolites.
Cai Y; Wang Z; Guo S; Lin C; Yao H; Yang Q; Wang Y; Yu X; He X; Sun W; Qiu S; Guo Y; Tang S; Xie Y; Zhang A
Trends Endocrinol Metab; 2023 Dec; 34(12):849-861. PubMed ID: 37739878
[TBL] [Abstract][Full Text] [Related]
24. Oncometabolites in Cancer: Current Understanding and Challenges.
Liu Y; Yang C
Cancer Res; 2021 Jun; 81(11):2820-2823. PubMed ID: 33762356
[TBL] [Abstract][Full Text] [Related]
25. Oncometabolites: Unconventional triggers of oncogenic signalling cascades.
Sciacovelli M; Frezza C
Free Radic Biol Med; 2016 Nov; 100():175-181. PubMed ID: 27117029
[TBL] [Abstract][Full Text] [Related]
26. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer.
King A; Selak MA; Gottlieb E
Oncogene; 2006 Aug; 25(34):4675-82. PubMed ID: 16892081
[TBL] [Abstract][Full Text] [Related]
27. Metabolic Rewiring and the Characterization of Oncometabolites.
Beyoğlu D; Idle JR
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34200553
[TBL] [Abstract][Full Text] [Related]
28. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.
Lehtonen HJ; Mäkinen MJ; Kiuru M; Laiho P; Herva R; van Minderhout I; Hogendoorn PC; Cornelisse C; Devilee P; Launonen V; Aaltonen LA
Int J Cancer; 2007 Sep; 121(6):1386-9. PubMed ID: 17520677
[TBL] [Abstract][Full Text] [Related]
29. Metabolic changes in cancer: beyond the Warburg effect.
Wu W; Zhao S
Acta Biochim Biophys Sin (Shanghai); 2013 Jan; 45(1):18-26. PubMed ID: 23257292
[TBL] [Abstract][Full Text] [Related]
30. Inborn and acquired metabolic defects in cancer.
Frezza C; Pollard PJ; Gottlieb E
J Mol Med (Berl); 2011 Mar; 89(3):213-20. PubMed ID: 21301796
[TBL] [Abstract][Full Text] [Related]
31. Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory.
Collins RRJ; Patel K; Putnam WC; Kapur P; Rakheja D
Clin Chem; 2017 Dec; 63(12):1812-1820. PubMed ID: 29038145
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
33. Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer.
Godel M; Ortone G; Anobile DP; Pasino M; Randazzo G; Riganti C; Kopecka J
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34065551
[TBL] [Abstract][Full Text] [Related]
34. Metabolic reprogramming of the tumor.
Ferreira LM; Hebrant A; Dumont JE
Oncogene; 2012 Sep; 31(36):3999-4011. PubMed ID: 22231450
[TBL] [Abstract][Full Text] [Related]
35. Implications of apoptosis regulators in tumorigenesis.
Malaguarnera L
Cancer Metastasis Rev; 2004; 23(3-4):367-87. PubMed ID: 15197336
[TBL] [Abstract][Full Text] [Related]
36. Linking metabolic reprogramming to therapy resistance in cancer.
Morandi A; Indraccolo S
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):1-6. PubMed ID: 28065746
[TBL] [Abstract][Full Text] [Related]
37. Chromatographic methods coupled to mass spectrometry for the determination of oncometabolites in biological samples-A review.
Asensio AF; Alvarez-González E; Rodríguez A; Sierra LM; Blanco-González E
Anal Chim Acta; 2021 Sep; 1177():338646. PubMed ID: 34482900
[TBL] [Abstract][Full Text] [Related]
38. Oncometabolites and the response to radiotherapy.
Xiang K; Jendrossek V; Matschke J
Radiat Oncol; 2020 Aug; 15(1):197. PubMed ID: 32799884
[TBL] [Abstract][Full Text] [Related]
39. Proteomics and metabolomics in cancer drug development.
D'Alessandro A; Zolla L
Expert Rev Proteomics; 2013 Oct; 10(5):473-88. PubMed ID: 24117204
[TBL] [Abstract][Full Text] [Related]
40. Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency.
Favier J; Brière JJ; Strompf L; Amar L; Filali M; Jeunemaitre X; Rustin P; Gimenez-Roqueplo AP;
Horm Res; 2005; 63(4):171-9. PubMed ID: 15795514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
